HDAC-targeting epigenetic modulators for cancer immunotherapy.

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Histone deacetylase (HDAC) inhibitors are explored for cancer immunotherapy, demonstrating potential therapeutic effects.
• Existing small molecule HDAC inhibitors often exhibit limited clinical efficacy and significant toxicity.
• Advanced HDAC modulators, including PROTAC degraders and dual-acting agents, are emerging as superior alternatives.

Purpose of the Study:

• To review recent advancements in HDAC-based drug discovery for cancer immunotherapy.
• To focus on HDAC inhibitor combination therapies and novel HDAC-targeting strategies.
• To discuss co-crystal structures, binding interactions, challenges, and future directions.

Main Methods:

• Literature review of HDAC inhibitor-based drug combination therapy.
• Analysis of selective HDAC inhibitors, dual-target inhibitors, and PROTAC HDAC degraders.
• Summary of co-crystal structures and binding interactions of HDAC inhibitors.

Main Results:

• HDAC inhibitor-based combination therapies and other modulators show enhanced efficacy over single-target inhibitors.
• Selective inhibitors, dual-target agents, and PROTAC degraders represent significant progress in HDAC-based drug discovery.
• Co-crystal structures provide insights into the binding mechanisms of HDAC inhibitors.

Conclusions:

• HDAC inhibitor-based combination therapies and novel HDAC modulators are crucial for advancing cancer immunotherapy.
• Further research into selective inhibitors, dual-target agents, and PROTAC degraders is warranted.
• Understanding binding interactions and addressing challenges will guide future HDAC-based drug development for cancer.